

Biomarker 2024

Pre-Mtg Agenda

Attendees are Provisional

Classical and Novel Biomarkers and Omics in CVD – Driving Toward More Medical Value

*Role of Biomarkers and Omics In Promoting
Progress in CV Science and CV Care*

**Nineteenth Annual Meeting: Transatlantic Heart Failure
Biomarker Working Group**

Cannes, France

April 27th – 28th, 2024

Scientific Programme

Chairmen:

Kirkwood F. Adams, Jr. (Chapel Hill, US)

Faiez Zannad (Nancy, FR)

Meeting Agenda

Cannes Hotel Le Gray d'Albion

Session 1 Latest Applications of Biomarkers in CVD Saturday Morning April 27, 2024

8:00 - 8:05 AM Overview *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)
Faiez Zannad, MD, PhD (Nancy, FR)*

Pre-Heart Failure – Using Biomarkers and Omics in Identification and Guiding Rx

Moderator *Kirkwood F. Adams, Jr, MD (Chapel Hill, US)*

8:05 - 8:45 AM Investigator Viewpoint *Faiez Zannad, MD, PhD (Nancy, FR)*
Investigator Viewpoint *Job A.J. Verdonschot, MD, MSc (Maastricht, NL)*
Investigator Viewpoint *Peter Liu MD, PhD (Ottawa, CA)*
Investigator Viewpoint *John Cleland, MD (Glasgow, UK)*
Industry Viewpoint *Juuso Blomster, MD, PhD (CardioSignal)*

8:45 - 9:20 AM Group Discussion

Current Application of Biomarkers in Clinical Cardiovascular Disease

Moderator *Alexandre Mebazaa, MD (Paris, FR)*

9:20 - 10:00 AM Investigator Viewpoint *Antoni Bayes-Genis, MD, PhD (Barcelona, ES)*
Investigator Viewpoint *Leong Ng, MD (Leicester, UK)*
Investigator Viewpoint *Berkan Kurt, MD (Aachen, DE)*
Investigator Viewpoint *Alexandre Mebazaa, MD (Paris, FR)*
Industry Viewpoint *Karine Bourgeois, PhD (4TEEN4)*
Industry Viewpoint *Peter Muntendam, MD (G3P, Inc)*

10:00 - 10:35 PM Group Discussion

10:35 - 10:50 AM Break

Optimal Integration of Biobanks Into CV Clinical Trials – Rationale and Challenges

Moderator *Faiez Zannad, MD, PhD (Nancy, FR)*

10:50 - 11:30 AM Investigator Viewpoint *Faiez Zannad, MD, PhD (Nancy, FR)*
Investigator Viewpoint *James Januzzi, Jr., MD (Boston, US)*
Industry Viewpoint *Mikhail Sumin, PhD (Boehringer-Ingelheim)*
Industry Viewpoint *Karsten Strauss, PhD (Olink)*
Industry Viewpoint *Mario Berger, PhD (Bayer)*

11:30 - 12:00 PM Group Discussion

12:00 - 1:00 PM Lunch

Meeting Agenda

Cannes Hotel Le Gray d'Albion

Session 2

Translation of Biomarker Science to Clinical Science

Saturday Afternoon April 27, 2024

Redefining HFpEF - Using Biomarkers to Understand Phenotypes and Rx Effects

Moderator *Arantxa González, PhD (Pamplona, ES)*

1:00 – 1:40 PM Investigator Viewpoint *Robert Mentz, MD (Durham, US)*
Investigator Viewpoint *Javed Butler, MD, MPH (Dallas, US)*
Investigator Viewpoint *Jasper Tromp, MD (Singapore, SG)*
Investigator Viewpoint *Arantxa González, PhD (Pamplona, ES)*

1:40 – 2:10 PM **Group Discussion**

Latest Update on Novel Biomarkers in Cardiovascular Disease

Moderator *John Cleland, MD (Glasgow, UK)*

2:10 - 2:40 PM **Investigator Viewpoint** *Camilia van der Hoef, BSc (Groningen, NL)*
Investigator Viewpoint *Lukas Baumhove, MD (Groningen, NL)*
Investigator Viewpoint *João Ferreira, MD, PhD (Porto, PT)*
Investigator Viewpoint *Noemi Pavo, MD, PhD (Vienna, AT)*

2:40 - 3:10 PM **Group Discussion**

Cardio-Renal Disease – Markers of Pathophysiology and Congestion

Moderator *Robert Mentz, MD (Durham, US)*

3:10 - 3:40 PM Investigator Viewpoint *Jozine ter Maaten, MD, PhD (Groningen, NL)*
Investigator Viewpoint *Christopher deFilippi, MD (Baltimore, US)*
Industry Viewpoint *Andrea Scalise MD (Bayer)*
Industry Viewpoint *Mario Berger, PhD (Bayer)*

3:40 - 4:15 PM **Group Discussion**

4:15 - 4:25 PM **Break**

Update on Cardio-Oncology – Clinical Insights from Biomarkers

Moderator *Leong Ng, MD (Leicester, UK)*

4:25 – 4:55 PM Investigator Viewpoint *Stefan Anker, MD, PhD (Berlin, DE)*
Investigator Viewpoint *Feriel Azibani, PhD (Paris, FR)*
Industry Viewpoint *Gillian Murtagh, MD, MBA (Abbott)*

4:55 – 5:30 PM **Group Discussion**

5:30 PM **Adjourn for the day**

Meeting Agenda

Cannes Hotel Le Gray d'Albion

Session 3

CV Biomarkers and Omics – Pathophysiology and Phenotyping

Sunday Morning April 28, 2024

Novel Pathophysiological Insights in Heart Failure: Focus On Omics and Biomarkers

Moderator *David Lanfear, MD, MS (Detroit, US)*

8:00 - 8:40 AM Investigator Viewpoint *Thomas Thum, MD, PhD (Hanover, DE)*
Investigator Viewpoint *Natalia Lopez, PhD (Pamplona, ES)*
Investigator Viewpoint *Jasper Tromp, MD (Singapore, SG)*
Investigator Viewpoint *David Lanfear, MD, MS (Detroit, US)*
Investigator Viewpoint *Tom Lumbers, MD (London, UK)*

8:40 - 9:15 AM **Group Discussion**

Clinical and Molecular Phenotyping to Enhance Precision Medicine in Heart Failure

Moderator *Job A.J. Verdonschot, MD, MSc (Maastricht, NL)*

9:15 - 9:55 AM Investigator Viewpoint *João Ferreira, MD, PhD (Porto, PT)*
Investigator Viewpoint *Christian Bar, PhD (Hanover, DE)*
Investigator Viewpoint *James Januzzi, Jr., MD (Boston, US)*
Industry Viewpoint *André Ziegler, PhD (Roche Dx)*

9:55 - 10:35 AM **Group Discussion**

10:35 - 10:45 AM **Break**

Reducing GDMT Treatment Gaps in CHF – Current Approaches and Clinical Benefits

Moderator *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*

10:45 - 11:30 AM Investigator Viewpoint *Alexandre Mebazaa, MD (Paris, FR)*
Investigator Viewpoint *James Januzzi, Jr., MD (Boston, US)*
Investigator Viewpoint *Ileana Piña, MD, MPH (Philadelphia, US)*
Investigator Viewpoint *Pierpaolo Pellicori, MD (Glasgow, UK)*
Investigator Viewpoint *Stephanie Dunlap, DO (Augusta, US)*
Investigator Viewpoint *Martin Hülsmann, MD (Vienna, AT)*

11:30 - 12:15 PM **Group Discussion**

12:15 - 1:15 PM **Lunch**

Meeting Agenda

Cannes Hotel Le Gray d'Albion

Session 4

Biomarkers for Precision Medicine

Sunday Afternoon April 28, 2024

Novel Strategies to Improve GDMT Treatment in CHF – Pivotal Studies Going Forward

Moderator *James Januzzi, Jr., MD (Boston, US)*

1:15 - 1:55 PM Investigator Viewpoint *Hans-Peter Brunner-La Rocca, MD (Maastricht, NL)*
Investigator Viewpoint *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*
Investigator Viewpoint *Alexandre Mebazaa, MD (Paris, FR)*
Investigator Viewpoint *Jasper Brugs, MD, PhD (Rotterdam, NL)*
Investigator Viewpoint *John Cleland, MD (Glasgow, UK)*

1:55 – 2:30 PM **Group Discussion**

Integration of CVD Omics into a Systems Biology Framework – Next Steps

Moderator *Alexandre Mebazaa, MD (Paris, FR)*

2:30 - 3:15 PM Investigator Viewpoint *Job A.J. Verdonschot, MD, MSc (Maastricht, NL)*
Investigator Viewpoint *Bart van Essen MD, PhD (Groningen, NL)*
Investigator Viewpoint *Tom Lumbers, MD (London, UK)*
Investigator Viewpoint *Nicolas Girerd, MD, PhD (Nancy, FR)*
Investigator Viewpoint *Wouter Ouwerkerk, PhD (Amsterdam, NL)*

3:15 - 3:55 PM **Group Discussion**

3:55 - 4:05 PM **Break**

Novel Drugs for Heart Failure: Biomarkers to Profile Patients and Guide Treatment

Moderator *Roberto Latini, MD (Milan, IT)*

4:05 - 4:35 PM Investigator Viewpoint *Kirkwood F. Adams, Jr., MD (Chapel Hill, US)*
Investigator Viewpoint *David Lanfear, MD, MS (Detroit, US)*
Investigator Viewpoint *Robert Mentz, MD (Durham, US)*

4:35 - 5:00 PM **Group Discussion**

5:00 PM **Meeting Wrap-up and Adjourn**